US patent notice for Umecrine's golexanolone in PBC symptoms, protection to 2042

what happened

Umecrine Cognition, a portfolio company of KDventures (Nasdaq Stockholm: KDV), has been told by the US Patent and Trademark Office that a patent application can move forward to grant. According to TradingView, the application covers using golexanolone to treat symptoms of primary biliary cholangitis (PBC), including fatigue, cognitive impairment and itching.

Once the patent is issued, the company expects it to protect the drug in the United States until at least 2042. Umecrine Cognition estimates that the US accounts for about 70 percent of the market potential for golexanolone in PBC, which is why it sees this protection as especially important.

why it matters

For investors this is mainly company-level news: the patent strengthens the firm's position in its key market but does not by itself change its financial outlook. The bigger near-term event is the readout of the Phase 1b/2a UCAB-CT-05 study, expected in early November 2026, which will show how well golexanolone performs against fatigue and cognitive symptoms in PBC patients.

tags

instruments